Navigation Links
HeartWare Announces Presentation of Clinical Data at the 25th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Lisbon
Date:9/28/2011

FRAMINGHAM, Mass. and SYDNEY, Sept. 28, 2011 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, announced today that clinical data for the HeartWare® Ventricular Assist System will be presented on Sunday, October 2, 2011 at the 25th EACTS Annual Meeting in Lisbon, Portugal.

A presentation by Mark S. Slaughter, M.D., entitled HeartWare®: Results of the ADVANCE Bridge to Transplant Trial, is scheduled for Sunday, October 2, 2011, at noon local time (7:00 a.m. U.S. Eastern Daylight Time) in Auditorium 1 of the Lisbon Congress Centre.  Dr. Slaughter, a principal investigator for HeartWare's ADVANCE trial, is Professor and Chief in the Division of Thoracic and Cardiovascular Surgery and Director of the Mechanical Assist Device and Heart Transplant Program at the University of Louisville.  The presentation will include clinical data from ADVANCE, as well as from the Continued Access Protocol for that study.

Investor Breakout Session and Webcast

Following the data presentation at EACTS, HeartWare management will host an investor breakout session with Dr. Slaughter, which will be available via audio webcast and conference call, at 2:00 p.m. local time (9:00 a.m. U.S. Eastern Daylight Time) on October 2, 2011 in Room 1.06 of the Lisbon Congress Centre.  

The audio from the meeting will be available to the public via webcast through the Company's website at (http://www.heartware.com/) by selecting "EACTS Investor Meeting" under the section titled "Corporate Presentations" on the home page.  A replay of the audio webcast will be available through the above weblink shortly following completion of the investor meeting. The audio for the meeting may also be accessed by dialing 1-800-215-2410 five minutes prior to the scheduled start time and referencing passcode 46162598.  For callers outside the United States, please dial +1-617-597-5410 and reference passcode 46162598.

Slides from the presentation at EACTS will be available following the presentation on the Company's International website (http://www.heartware.com) by selecting the International region, then Clinicians, then Clinical Trials.  

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  HeartWare has received CE Marking for the HeartWare System in the European Union.  The device is currently the subject of United States clinical trials for two indications: destination therapy and bridge-to-transplant under a continued access protocol and is not yet commercially available.  For additional information, please visit the Company's website at www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

For further information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartwareinc.com
Phone: +1 508 739 0864


'/>"/>
SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare to Present at The Lazard Capital Markets 3rd Annual Circulatory Assist Device Day
2. HeartWare to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference
3. HeartWare to Present at the Canaccord Genuity 31st Annual Growth Conference
4. HeartWare International Reports Second Quarter 2011 Revenues of $20.4 Million; 109% Increase From $9.8 Million in Second Quarter 2010
5. HeartWare to Report Financial Results for Second Quarter of 2011
6. HeartWare to Present at the Wells Fargo 2011 Healthcare Conference
7. HeartWare to Present at the 2011 Bank of America Merrill Lynch Health Care Conference
8. HeartWare International Reports First Quarter 2011 Revenues of $18.0 Million; 68% Increase From $10.7 Million in First Quarter 2010
9. HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients
10. HeartWare Announces Presentations at The International Society of Heart and Lung Transplantation Annual Meeting
11. HeartWare International Receives Approval From the Therapeutic Goods Administration (TGA) in Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... Ill. , July 11, 2017  Sysmex ... and urinalysis diagnostic testing equipment as well as ... innovation: a way to make quality assurance easier ... processes. "Sysmex is well known for the innovation ... Quality Monitor elevates quality assurance processes to ...
(Date:7/10/2017)... COLUMBIA, S.C. , July 10, 2017 /PRNewswire/ ... product purchasing and patient support services organization serving ... announced today the launch of four significant, value-added ... into market insights, better manage reimbursement and improve ... Ig and factor therapies. ...
(Date:7/5/2017)... JERUSALEM , July 5, 2017 ... www.oramed.com ), a clinical-stage pharmaceutical company ... today that it has received approval from the Israel Securities ... Stock Exchange (TASE). Oramed common stock will commence trading on ... Based on the current market capitalization of the Company, it ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... 21, 2017 , ... Sharon Kleyne is proud of the ... research center at Bio-Logic Aqua Research® Water Life Science®, has been released in ... sufferers of blindness. “We think that Nature’s Tears® EyeMist® will contribute to eliminating ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... ligament (ACL) offer patients improved quality of life five years after injury, according ... Annual Meeting in Toronto, Ontario, Canada. The study followed patients for five ...
(Date:7/20/2017)... ... July 20, 2017 , ... ChenMed , a ... joined JenCare Senior Medical Center as Richmond Chief Medical Officer. Dr. ... Medicine, and Associate Chief Medical Officer of Ambulatory Services for the UVA Health System, ...
(Date:7/20/2017)... , ... July 20, 2017 , ... ... firm headquartered in Houston, is pleased to announce their expansion to the Midwest ... housing experience, directors Alysse Hollis and Ronald Bell, and of counsels, John Peck ...
(Date:7/20/2017)... ... July 20, 2017 , ... Team Type 1 Foundation, a nonprofit organization pursuing ... by diabetes, is teaming up with a Microsoft Corp. employee-led hackathon team for the ... 24th. , “Team Type 1’s mission overlaps seamlessly with Microsoft’s mission to empower ...
Breaking Medicine News(10 mins):